Tenpoint Therapeutics

Biotechnology Research • London Innovation Centre, 20 Water Street, United Kingdom • 51-100 Employees

Company overview

Headquarters	London Innovation Centre, 20 Water Street, 4th Floor Office 3, Wood Wharf, London, E14 9GG, GB
Phone number	+448002814536
Website	tenpointtherapeutics.com
NAICS	541714
Keywords	Optometry, Eye Health, Ophthalmology, Glaucoma, AMD, Macular Degeneration, Regenerative Medicine, Presbyopia, Dry Eye Disease, Ocular Surface Disease
Founded	2019
Employees	51-100
Socials

Key Contacts at Tenpoint Therapeutics

Rob Sambursky

Founder And Director

Tiago Ferreira

Director Of Preclinical Ophthalmology

Joseph Ponzo

Executive Director Of Medical Marketing

Henric Bjarke

Chief Executive Officer

Nicholas Langevin

Executive Director, Regulatory Affairs

Ryan Vallee

Area Sales Director

Julie Dalsis

Area Sales Director

Gabriella Rolli

Chief Technology Officer

Sandra Marucci

Executive Director, Field And Marketing Operations

David Mba

Associate Director Clinical Operations

Tenpoint Therapeutics Email Formats

Tenpoint Therapeutics uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@tenpoint-tx.com), used 92.3% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@tenpoint-tx.com	92.3%
{first name}.{last name}	john.doe@tenpoint-tx.com	7.7%

About Tenpoint Therapeutics

Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the NDA and has received a Prescription Drug User Fee Act (PDUFA) date from the US FDA of Jan 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy.

Tenpoint Therapeutics revenue & valuation

Annual revenue	$4,000,000
Revenue per employee	$58,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$12,800,000
Total funding	$20,000,000

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Director

Vice President

C-Suite

Employees by Department

Tenpoint Therapeutics has 43 employees across 12 departments.

Departments

Number of employees

Funding Data

Explore Tenpoint Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-09-10	12	$20,000,000

Funding Insights

$20,000,000

Total funding amount

$20,000,000

Most recent funding amount

Number of funding rounds

Tenpoint Therapeutics Tech Stack

Discover the technologies and tools that power Tenpoint Therapeutics's digital infrastructure, from frameworks to analytics platforms.

jQuery CDN

CDN

Gravity Forms

Form builders

Vimeo

Video players

Cookie Control

Cookie compliance

Embedly

Widgets

jQuery-pjax

Mobile frameworks

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

HTTP/3

Miscellaneous

HSTS

Security

Frequently asked questions

Tenpoint Therapeutics is located in London Innovation Centre, 20 Water Street, GB.

You can reach Tenpoint Therapeutics at +448002814536.

Tenpoint Therapeutics was founded in 2019, making it 7 years old. The company has established itself as a significant player in its industry over this time.

Tenpoint Therapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Tenpoint Therapeutics has raised a total of $20,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.